Suppr超能文献

错构瘤综合征成年患者结直肠癌监测的检测与检出率

Detection and Yield of Colorectal Cancer Surveillance in Adults with Hamartoma Tumour Syndrome.

作者信息

Drissen Meggie M C M, Vos Janet R, van der Biessen-van Beek Dorien T J, van der Post Rachel S, Nagtegaal Iris D, van Kouwen Mariëtte C A, Bisseling Tanya M, Hoogerbrugge Nicoline

机构信息

Department of Human Genetics, Radboud University Medical Center, 6500 Nijmegen, The Netherlands.

Radboud University Medical Center, Radboud Institute for Health Sciences, 6525 Nijmegen, The Netherlands.

出版信息

Cancers (Basel). 2022 Aug 19;14(16):4005. doi: 10.3390/cancers14164005.

Abstract

Colorectal cancer surveillance (CCS) with colonoscopy every five years is advised for Hamartoma Tumour Syndrome (PHTS) patients aged ≥40 due to an increased colorectal cancer (CRC) risk. However, data to support CCS guidelines are scarce and available CRC risks are low (0-5% at age 50) and likely overestimated. We aimed to assess the detection and yield of CCS for PHTS patients without a CRC history. A retrospective cohort study including PHTS patients aged ≥40 with CCS at a PHTS expertise centre between 2011 and 2022. Adenomas with a ≥10 mm size, (tubulo)villous histology, or high-grade dysplasia were considered advanced. During 67 follow-up years, 37 patients (median age 47 years) underwent 61 colonoscopies. CCS yielded no CRCs. Adenomas were diagnosed in 13/37 (35%) patients during 23/100 colonoscopies (95% CI: 14-36), including one advanced adenoma. Baseline adenoma detection rates were similar to follow-up and higher in patients aged above 50 (50/100, 95% CI: 24-76) vs. age 50 or below (11/100, 95% CI: 3-30; = 0.021). The low CRC and advanced adenoma yield allow for a more personalised surveillance program. Following our findings combined with literature on CRC risk and progression, we suggest starting CCS at age 40 with variable follow-up intervals between 1 and 10 years depending on previous colonoscopy findings.

摘要

由于患结直肠癌(CRC)风险增加,建议年龄≥40岁的错构瘤肿瘤综合征(PHTS)患者每五年进行一次结肠镜检查的结直肠癌监测(CCS)。然而,支持CCS指南的数据很少,现有的CRC风险很低(50岁时为0-5%),而且可能被高估了。我们旨在评估无CRC病史的PHTS患者的CCS检测率和检出率。一项回顾性队列研究,纳入了2011年至2022年间在一个PHTS专业中心接受CCS的年龄≥40岁的PHTS患者。大小≥10毫米、(小管状)绒毛状组织学或高级别发育异常的腺瘤被视为高级别腺瘤。在67年的随访期间,37名患者(中位年龄47岁)接受了61次结肠镜检查。CCS未检出CRC。在23/100次结肠镜检查中,有13/37(35%)的患者被诊断出腺瘤(95%CI:14-36),其中包括1例高级别腺瘤。基线腺瘤检出率与随访时相似,50岁以上患者(50/100,95%CI:24-76)高于50岁及以下患者(11/100,95%CI:3-30;P = 0.021)。CRC和高级别腺瘤的低检出率使得可以制定更个性化的监测方案。结合我们的研究结果以及关于CRC风险和进展的文献,我们建议在40岁开始进行CCS,根据之前的结肠镜检查结果,随访间隔在1至10年之间变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f485/9406787/554390699c82/cancers-14-04005-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验